RU2696572C2 - 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение - Google Patents

3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение Download PDF

Info

Publication number
RU2696572C2
RU2696572C2 RU2014138194A RU2014138194A RU2696572C2 RU 2696572 C2 RU2696572 C2 RU 2696572C2 RU 2014138194 A RU2014138194 A RU 2014138194A RU 2014138194 A RU2014138194 A RU 2014138194A RU 2696572 C2 RU2696572 C2 RU 2696572C2
Authority
RU
Russia
Prior art keywords
compound according
present
paragraphs
independently
cancer
Prior art date
Application number
RU2014138194A
Other languages
English (en)
Russian (ru)
Other versions
RU2014138194A (ru
Inventor
Алан Эшворт
Кристофер Джеймс ЛОРД
Ричард Джеймс Роуланд ЭЛЛИОТТ
Дэн Никулеску-Дувас
Родерик ПОРТЕР
Рэймонд Джон Боффи
Мелани Джейн БЕЙФОРД
Стюарт ФЁРТ-КЛАРК
Эшли Николас ДЖАРВИС
Тревор Роберт ПЕРРИОР
Ребека Элизабет КИ
Original Assignee
Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) filed Critical Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе)
Publication of RU2014138194A publication Critical patent/RU2014138194A/ru
Application granted granted Critical
Publication of RU2696572C2 publication Critical patent/RU2696572C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2014138194A 2012-03-07 2013-03-07 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение RU2696572C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607680P 2012-03-07 2012-03-07
US61/607,680 2012-03-07
PCT/GB2013/050561 WO2013132253A1 (en) 2012-03-07 2013-03-07 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Publications (2)

Publication Number Publication Date
RU2014138194A RU2014138194A (ru) 2016-04-27
RU2696572C2 true RU2696572C2 (ru) 2019-08-05

Family

ID=47891779

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014138194A RU2696572C2 (ru) 2012-03-07 2013-03-07 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение

Country Status (13)

Country Link
US (1) US9193689B2 (https=)
EP (1) EP2822656B1 (https=)
JP (1) JP6082409B2 (https=)
KR (1) KR102104144B1 (https=)
CN (1) CN104302358B (https=)
AU (1) AU2013229229B2 (https=)
CA (1) CA2865511A1 (https=)
DK (1) DK2822656T3 (https=)
ES (1) ES2611504T3 (https=)
IN (1) IN2014MN01875A (https=)
MX (1) MX346147B (https=)
RU (1) RU2696572C2 (https=)
WO (1) WO2013132253A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
KR102083154B1 (ko) * 2012-08-08 2020-03-02 메르크 파텐트 게엠베하 （아자―）이소퀴놀리논 유도체
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
ES2969565T3 (es) * 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
MX2018006474A (es) 2015-12-02 2018-08-01 Syngenta Participations Ag Derivados de oxadiazol microbicidas.
UY37623A (es) 2017-03-03 2018-09-28 Syngenta Participations Ag Derivados de oxadiazol tiofeno fungicidas
WO2018219773A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Fungicidal compositions
WO2018219825A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
EP3644743B1 (en) 2017-06-28 2022-10-26 Syngenta Participations AG Fungicidal compositions
WO2019011928A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
BR112020000456A2 (pt) 2017-07-11 2020-07-21 Syngenta Participations Ag derivados oxadiazol microbiocidas
WO2019011926A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011923A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
BR112020000371A2 (pt) 2017-07-12 2020-07-14 Syngenta Participations Ag derivados de oxadiazol microbiocidas
BR112020000463A2 (pt) 2017-07-13 2020-07-21 Syngenta Participations Ag derivados oxadiazol microbiocidas
EP3459469A1 (en) 2017-09-23 2019-03-27 Universität Zürich Medical occluder device
US12402885B2 (en) 2017-09-23 2025-09-02 Universität Zürich Medical occlusion device
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3823966A1 (en) 2018-07-16 2021-05-26 Syngenta Crop Protection AG Microbiocidal oxadiazole derivatives
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
AR118673A1 (es) 2019-04-18 2021-10-20 Syngenta Crop Protection Ag Procedimiento para la preparación de derivados de oxadiazol microbiocidas
CN114641242B (zh) 2019-09-26 2025-11-18 苏黎世大学 左心耳闭塞装置
US12459899B2 (en) * 2019-10-30 2025-11-04 DIGMBIO, Inc. Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
US12564408B2 (en) 2020-03-25 2026-03-03 Universitat Zurich Medical occluder delivery systems
EP4232925A1 (en) 2020-10-21 2023-08-30 Verint Americas Inc. System and method of automated determination of use of sensitive information and corrective action for improper use
CN117043302A (zh) 2021-03-18 2023-11-10 默克专利有限公司 用于有机电致发光器件的杂芳族化合物
WO2022235492A1 (en) * 2021-05-04 2022-11-10 Board Of Regents, The University Of Texas System Indanone and tetralone-keto or hydroxyl oximes as cancer therapeutics
AR126196A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Proceso para preparar inhibidores de egfr
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
CN115572262B (zh) * 2022-10-27 2024-08-27 厦门沃克沃德医药科技有限公司 一种异喹啉衍生物及其制备方法
WO2024238871A1 (en) * 2023-05-18 2024-11-21 Rectify Pharmaceuticals, Inc. Aryl sulfonamide compounds and their use in treating medical conditions
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds
WO2025136936A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Agonists of trem2 activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544194A1 (en) * 2002-07-24 2005-06-22 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
EP1557414A1 (en) * 2002-10-01 2005-07-27 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US20070049555A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EA201070196A1 (ru) * 2007-07-27 2010-08-30 Санофи-Авентис Производные 1-оксо-1,2-дигидроизохинолин-5-карбоксамидов и 4-оксо-3,4-дигидрохиназолин-8-карбоксамидов, их получение и их применение в терапии

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2851458A (en) 1955-06-08 1958-09-09 Burroughs Wellcome Co Diquaternary compounds and the manufacture thereof
US3464563A (en) 1967-02-06 1969-09-02 American Air Filter Co Liquid filter apparatus
US4678500A (en) 1984-06-29 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
ATE404539T1 (de) 1997-10-02 2008-08-15 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EA010408B1 (ru) 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
WO2005075432A1 (ja) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用
WO2005113540A1 (ja) 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
PT1807077T (pt) 2004-10-22 2017-01-06 Janssen Pharmaceutica Nv Inibidores de quinase c-fms
MX2007007027A (es) 2004-12-16 2007-07-04 Hoffmann La Roche Derivados piperazinilpiridina como agentes anti-obesidad.
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027650A1 (en) 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
KR101598397B1 (ko) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
MX2011008641A (es) 2009-03-06 2011-09-06 Hoffmann La Roche Compuestos heterociclicos antivirales.
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
US8841289B2 (en) 2009-10-13 2014-09-23 Merck Sharp & Dohme B.V. Heterocyclic derivatives
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
AU2012282076A1 (en) 2011-07-13 2014-02-27 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
EP2731942B1 (en) 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
EA027800B1 (ru) 2011-11-25 2017-09-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1
MX353578B (es) 2011-12-31 2018-01-19 Beigene Ltd Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
JP2015505542A (ja) 2012-01-28 2015-02-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザ複素環式化合物
WO2013116182A1 (en) 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
UA116627C2 (uk) 2012-02-09 2018-04-25 Мерк Патент Гмбх Похідні тетрагідрохіназоліну як інгібітори tank та parp
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CA2868620C (en) 2012-03-28 2020-02-25 Dieter Dorsch Bicyclic pyrazinone derivatives
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
AU2013257018B2 (en) 2012-05-04 2017-02-16 Merck Patent Gmbh Pyrrolotriazinone derivatives
WO2013177349A2 (en) 2012-05-25 2013-11-28 Glaxosmithkline Llc Quinazolinediones as tankyrase inhibitors
CN104540830A (zh) 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
CN104350056A (zh) 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
EP2864330A1 (en) 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG Pyrrolopyrazone inhibitors of tankyrase
HK1201066A1 (en) 2012-06-20 2015-08-21 霍夫曼-拉罗奇有限公司 Pyranopyridone inhibitors of tankyrase
KR102083154B1 (ko) 2012-08-08 2020-03-02 메르크 파텐트 게엠베하 （아자―）이소퀴놀리논 유도체
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
AR092211A1 (es) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
RU2650107C2 (ru) 2012-09-26 2018-04-09 Мерк Патент Гмбх Производные хиназолинона в качестве ингибиторов parp
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544194A1 (en) * 2002-07-24 2005-06-22 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
EP1557414A1 (en) * 2002-10-01 2005-07-27 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US20070049555A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EA201070196A1 (ru) * 2007-07-27 2010-08-30 Санофи-Авентис Производные 1-оксо-1,2-дигидроизохинолин-5-карбоксамидов и 4-оксо-3,4-дигидрохиназолин-8-карбоксамидов, их получение и их применение в терапии

Also Published As

Publication number Publication date
DK2822656T3 (en) 2017-01-30
EP2822656B1 (en) 2016-10-19
AU2013229229A1 (en) 2014-09-25
KR20150001734A (ko) 2015-01-06
JP6082409B2 (ja) 2017-02-15
WO2013132253A1 (en) 2013-09-12
JP2015512885A (ja) 2015-04-30
US20150099732A1 (en) 2015-04-09
ES2611504T3 (es) 2017-05-09
CN104302358B (zh) 2017-12-05
EP2822656A1 (en) 2015-01-14
KR102104144B1 (ko) 2020-04-23
MX2014010509A (es) 2014-10-14
CA2865511A1 (en) 2013-09-12
US9193689B2 (en) 2015-11-24
CN104302358A (zh) 2015-01-21
AU2013229229B2 (en) 2017-10-19
IN2014MN01875A (https=) 2015-07-03
RU2014138194A (ru) 2016-04-27
MX346147B (es) 2017-03-09

Similar Documents

Publication Publication Date Title
RU2696572C2 (ru) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
EP3044221B1 (en) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN102933572B (zh) 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法
JP5592890B2 (ja) ピロロトリアジンキナーゼ阻害剤
JP2022503942A (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
US8841304B2 (en) Pyrrolopyridines as kinase inhibitors
JP2016523922A (ja) Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
JP2016505042A (ja) Ｒｏｃｋ阻害剤としてのフタラジノンおよびイソキノリノン
KR20190076033A (ko) αV 인테그린 길항제로서의 인다졸 유도체
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
KR20160050080A (ko) 트라이아졸로피리딘 화합물, 이의 조성물 및 사용 방법
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
CN117285485A (zh) 一种双磺酰胺类衍生物及其制备方法和应用
US20140221370A1 (en) Pyrrolopyridines as kinase inhibitors
WO2025161764A1 (zh) 一种myc抑制剂及其制备方法和应用
WO2003027093A1 (en) Chemical compounds
US20250312335A1 (en) Flt combination therapy for cancer and compositions therefor

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180109

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20180109